Optimization of parasite genotyping to improve malaria therapy reports
Official title: Optimization of genotyping and analysis pipelines for evaluating antimalarial therapeutic efficacy studies
Funded at University of California, San Francisco · NIH-11597934 · Data updated 2026-11-12
Researchers are improving how parasite DNA is used to judge whether antimalarial treatments work, focusing on people in sub-Saharan Africa who have falciparum malaria.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of California, San Francisco NIH-funded |
| Lab location | 1 site (San Francisco, United States) |
| Project start | September 3, 2026 |
| Project end | August 31, 2029 |
| Funding year | 2026 |
| Award (this year) | $1 |
| NIH project number | 3R01AI191138-01A1S1 |
| Project ID | NIH-11597934 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates are patients with falciparum malaria in sub-Saharan Africa who undergo therapeutic efficacy studies and have follow-up samples available for genotyping.
✕Less likely to help
Patients not enrolled in TES or without follow-up samples may not benefit directly.
What this research studies
This project aims to refine the genetic methods used to tell whether a patient’s malaria comes back because the treatment failed or because a new infection occurred. By updating the genotyping and analysis of samples taken before treatment and at recurrence, clinicians can make more accurate decisions about therapy effectiveness. The work will compare current methods with improved techniques to reduce bias and misclassification in TES outcomes. The study is rooted in real-world patient data from areas affected by drug resistance, and it seeks to provide clearer guidance for policymakers on which drugs to use next. The project will be conducted at UC San Francisco under the leadership of Dr. Bryan R. Greenhouse and collaborators, with a focus on methods applicable to African settings.
Why it matters
Potential benefit: If successful, the new genotyping and analysis methods could lead to more reliable measurements of drug efficacy and better-informed treatment choices for falciparum malaria.
How similar studies have gone: Previous efforts show that improved genotyping can change TES outcome classifications, but current methods remain biased and inconsistent.
Where this research is happening
-
University of California, San Francisco
San Francisco, United States Active
Researchers
- Principal investigator: Greenhouse, Bryan R — University of California, San Francisco
- Study coordinator: Greenhouse, Bryan R
Related research
Other NIH-funded projects on the same topics.
-
How cancer cells use exosomes to evade the immune system
This study is looking at how cancer cells use tiny bubbles called exosomes to hide proteins that can keep your immune system from fighting the tumor, and by figuring this out, the researchers hope to help doctors understand why some people respond well to cancer treatments while others don’t, ultimately aiming to creat
-
Reducing harm from smoking using electronic cigarettes
This study is looking at whether using electronic cigarettes can be a safer option for people who smoke traditional cigarettes, by comparing the health effects and exposure to harmful substances between the two.
-
Understanding how knee pain and knee obesity and muscle loss affect knee osteoarthritis
This project looks at how knee swelling, excess knee fat, and muscle loss relate to pain and structural changes in knee osteoarthritis in adults.
-
Cutaneous opioid signals in skin inflammation
A mentor-identified clinician-researcher at UCSF is studying how natural skin opioids regulate itch and pain in inflammatory skin conditions like eczema and hidradenitis, with plans to map where these opioids come from and how they affect skin nerves.
-
Pooling international data to understand long-term bisphosphonate use and atypical femur fractures
This project combines large patient datasets from multiple countries to understand how long-term bisphosphonate use relates to rare hip and thigh bone fractures, helping doctors and patients make safer treatment choices.
-
Airway cell and immune cell talks in lung transplant failure
This grant tests how airway cells and immune cells interact to drive chronic rejection after lung transplant, with the goal of slowing or preventing scar-like damage.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.